Trial · NCT00694369

A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092)

NCT00694369, Phase 3, Completed, Organon and Co; results first posted 2010-01-29

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092). Trials, record NCT00694369. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00694369

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092)
NCT number: NCT00694369
Status: Completed
Phases: Phase 3
Enrollment: 588 participants, actual
Lead sponsor: Organon and Co
Conditions: Postoperative Dental Pain
Interventions: Comparator: etoricoxib, Comparator: ibuprofen, Comparator: acetaminophen + codeine, Comparator: placebo
First posted: 2008-06-10
Last updated: 2022-02-09
Results first posted: 2010-01-29

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Total Pain Relief Score Over the First 6 Hours Post the Initial Day 1 Dose of the Study Medication (TOPAR6)	Over the first 6 hours post the initial Day 1 dose of the study medication	TOPAR6 was calculated by multiplying the pain relief (PR) score (0- to 4-point Likert scale, with 0=None, and 4=Complete for pain relief) at each time point by the duration (in hours) since the preceding time point, and summing these weighted values up to 6 hours post the initial Day 1 dose. The range of TOPAR6 score is 0 to 24.
Secondary	Patient's Global Assessment of Study Medication at 24 Hours Post the Initial Day 1 Dose of the Study Medication	At 24 hours post the initial Day 1 dose of the study medication	Patient's Global Assessment of Study Medication was on 0- to 4- point scale, with 0=Poor, and 4=Excellent for patient's rating of the study medication for pain.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Total Pain Relief Score Over the First 6 Hours Post the Initial Day 1 Dose of the Study Medication (TOPAR6)	Over the first 6 hours post the initial Day 1 dose of the study medication	Full Analysis Set population (all randomized patients who received at least 1 dose of study treatment and had at least 1 post-baseline PR data over the first 6 hours). Observed PR was used up to rescue. Missing data was imputed by linear interpolation at time points before rescue, by last-observation-carried-forward at time points after rescue.	Units on a Scale	LEAST_SQUARES_MEAN
SECONDARY	Patient's Global Assessment of Study Medication at 24 Hours Post the Initial Day 1 Dose of the Study Medication	At 24 hours post the initial Day 1 dose of the study medication	Full Analysis Set population (all randomized patients who received at least 1 dose of study treatment and had at least 1 post-baseline assessment at 24 hours). Observed data was used. Forty patients were excluded from the analysis due to no measurement at 24 hours after the initial Day 1 dose.	Participants	NUMBER

Source ClinicalTrials.gov

Results by group30

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Total Pain Relief Score Over the First 6 Hours Post the Initial Day 1 Dose of the Study Medication (TOPAR6)	Placebo		5.08	Standard Error 0.86	Units on a Scale
Total Pain Relief Score Over the First 6 Hours Post the Initial Day 1 Dose of the Study Medication (TOPAR6)	Etoricoxib 90 mg		16.10	Standard Error 0.42	Units on a Scale
Total Pain Relief Score Over the First 6 Hours Post the Initial Day 1 Dose of the Study Medication (TOPAR6)	Etoricoxib 120 mg		15.73	Standard Error 0.59	Units on a Scale
Total Pain Relief Score Over the First 6 Hours Post the Initial Day 1 Dose of the Study Medication (TOPAR6)	Ibuprofen 2400 mg		15.67	Standard Error 0.42	Units on a Scale
Total Pain Relief Score Over the First 6 Hours Post the Initial Day 1 Dose of the Study Medication (TOPAR6)	Acetaminophen 2400 mg/Codeine 240 mg		11.83	Standard Error 0.74	Units on a Scale
Patient's Global Assessment of Study Medication at 24 Hours Post the Initial Day 1 Dose of the Study Medication	Placebo	Poor	19		Participants
Patient's Global Assessment of Study Medication at 24 Hours Post the Initial Day 1 Dose of the Study Medication	Etoricoxib 90 mg	Poor	12		Participants
Patient's Global Assessment of Study Medication at 24 Hours Post the Initial Day 1 Dose of the Study Medication	Etoricoxib 120 mg	Poor	7		Participants
Patient's Global Assessment of Study Medication at 24 Hours Post the Initial Day 1 Dose of the Study Medication	Ibuprofen 2400 mg	Poor	6		Participants
Patient's Global Assessment of Study Medication at 24 Hours Post the Initial Day 1 Dose of the Study Medication	Acetaminophen 2400 mg/Codeine 240 mg	Poor	1		Participants

1 to 10 of 30Source ClinicalTrials.gov

See all 30 results by group

Participant flow15

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	46
Overall Study	STARTED	Etoricoxib 90 mg	191
Overall Study	STARTED	Etoricoxib 120 mg	97
Overall Study	STARTED	Ibuprofen 2400 mg	192
Overall Study	STARTED	Acetaminophen 2400 mg/Codeine 240 mg	62
Overall Study	COMPLETED	Placebo	45
Overall Study	COMPLETED	Etoricoxib 90 mg	188
Overall Study	COMPLETED	Etoricoxib 120 mg	95
Overall Study	COMPLETED	Ibuprofen 2400 mg	189
Overall Study	COMPLETED	Acetaminophen 2400 mg/Codeine 240 mg	56

1 to 10 of 15Source ClinicalTrials.gov

See all 15 participant flow

Adverse events450

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Lymphadenopathy	Blood and lymphatic system disorders	Placebo	0	46
other	Lymphadenopathy	Blood and lymphatic system disorders	Etoricoxib 90 mg	0	191
other	Lymphadenopathy	Blood and lymphatic system disorders	Etoricoxib 120 mg	0	97
other	Lymphadenopathy	Blood and lymphatic system disorders	Ibuprofen 2400 mg	0	192
other	Lymphadenopathy	Blood and lymphatic system disorders	Acetaminophen 2400 mg/Codeine 240 mg	1	62
other	Palpitations	Cardiac disorders	Placebo	0	46
other	Palpitations	Cardiac disorders	Etoricoxib 90 mg	1	191
other	Palpitations	Cardiac disorders	Etoricoxib 120 mg	0	97
other	Palpitations	Cardiac disorders	Ibuprofen 2400 mg	0	192
other	Palpitations	Cardiac disorders	Acetaminophen 2400 mg/Codeine 240 mg	0	62

1 to 10 of 450Source ClinicalTrials.gov

See all 450 adverse events

Adverse event totals15

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo
Total, all-cause mortality	Etoricoxib 90 mg
Total, all-cause mortality	Etoricoxib 120 mg
Total, all-cause mortality	Ibuprofen 2400 mg
Total, all-cause mortality	Acetaminophen 2400 mg/Codeine 240 mg
Total, other adverse events	Placebo	12	46
Total, other adverse events	Etoricoxib 90 mg	54	191
Total, other adverse events	Etoricoxib 120 mg	28	97
Total, other adverse events	Ibuprofen 2400 mg	57	192
Total, other adverse events	Acetaminophen 2400 mg/Codeine 240 mg	35	62

1 to 10 of 15Source ClinicalTrials.gov

See all 15 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
23247002	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00694369

GET https://conductscience.org/api/trials/v1/NCT00694369/results?page=2

API reference For AI assistants